Noninvasive biomarker testing for liver fibrosis: The laboratory’s role in advancing MASLD and MASH patient management

For more on MASLD and MASH, be sure to check out our 10/28 webinar, Liver disease in focus: Prevalence, disease burden, risk factors, and guidelines in MASLD and MASH.

Description

This webinar will explore the growing burden of MASLD and MASH in the US with an emphasis on the urgent need for early detection to improve patient outcomes. Attendees will gain insights into the expanding role of noninvasive blood-based biomarker testing for MASLD and MASH management. Drawing on real-world experience from the Mayo Clinic, Dr Nikola Baumann will provide laboratory validation strategies, cross-lab comparisons, and reporting considerations for novel noninvasive blood-based tests to ensure clarity and clinical confidence for both clinicians and patients.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), fellows, residents, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this webinar, participants will be able to:

• Describe the significance and growing burden of MASLD and MASH in the US and the importance of early detection in improving patient outcomes.
• Discuss the rising demand for noninvasive biomarker testing for liver fibrosis, driven by limited access to imaging technologies and updated US guidelines recommending blood-based biomarkers for patient management.
• Summarize key laboratory considerations for implementing novel FDA-cleared noninvasive biomarker tests, including validation, reporting, and result interpretability for clinicians and patients.

Faculty

Nikola Baumann, PhD, DABCC
Vice Chair of Quality and CLIA Lab Director
Co-Director, Central Clinical Laboratory and Central Processing
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Nikola Baumann, PhD, DABCC
  • Honorarium/Expenses: Siemens Healthineers

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity will be submitted for 1.0 ACCENT continuing education credit.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].